+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 12Years - 30Years
All Genders
Healthy Volunteers
ID06655324

Evaluating the Safety, Tolerability, and Immune Response of V350A and V350B Vaccines Compared to Placebo in Healthy Participants Aged 12 to 30

Led by Merck Sharp & Dohme LLC · Updated on 2026-10-27

250

Participants Needed

9

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of two new vaccines, V350A and V350B, designed to prevent diseases related to Epstein Barr virus EBV, a virus linked to infectious mononucleosis, certain cancers, and multiple sclerosis. This Phase 1 trial involves healthy participants aged 12 to 30 years and aims to understand how well these vaccines are tolerated and their immune response. Participants are randomly assigned to receive one of three treatments V350A vaccine, V350B vaccine, or a placebo. Each participant will receive three vaccinations administered by intramuscular injection on Day 1, Month 2, and Month 6. The study follows a sequential design and uses a triple-blind setup to ensure unbiased results. During the study, participants will be closely monitored for side effects related to the injections up to 18 months. Researchers will record injection site reactions, systemic symptoms, immediate and unsolicited adverse events, as well as serious and medically attended adverse events. Immune responses will be measured by antibody levels against EBV antigens. The total participation duration spans up to approximately 18 months, including safety and immune response evaluations.

CONDITIONS

Brief Title

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here